Back to Journals » Patient Preference and Adherence » Volume 11

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Authors Pergolizzi Jr JV, Raffa RB, Pappagallo M, Fleischer C, Pergolizzi, III J, Zampogna G, Duval E, Hishmeh J, LeQuang JA, Taylor R Jr

Received 5 May 2016

Accepted for publication 18 August 2016

Published 17 January 2017 Volume 2017:11 Pages 107—119

DOI https://doi.org/10.2147/PPA.S78042

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen

Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Marco Pappagallo,4 Charles Fleischer,1 Joseph Pergolizzi III,1 Gianpietro Zampogna,5 Elizabeth Duval,1 Janan Hishmeh,1 Jo Ann LeQuang,1 Robert Taylor Jr1

1NEMA Research, Inc., Naples, FL, 2University of Arizona College of Pharmacy, University of Arizona, Tucson, AZ, 3Temple University School of Pharmacy, Temple University, Philadelphia, PA, 4Department of Medicine, Albert Einstein College of Medicine, New York, NY, 5Department of Medicine, St. Luke’s Hospital, Cleveland, OH, USA

Abstract: Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting μ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting μ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.

Keywords: opioid-induced constipation, opioid bowel disorder, PAMORA, peripherally acting mu-opioid receptor antagonist, noncancer pain patients, opioid-associated side effects

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Revisiting transdermal scopolamine for postoperative nausea and vomiting

Pergolizzi JV, Raffa RB, Zampogna G, Annabi HM, Pallaria TJ, Taylor R

Research and Reports in Transdermal Drug Delivery 2015, 4:35-44

Published Date: 13 August 2015

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain

Pergolizzi Jr JV, van de Laar M, Langford R, Mellinghoff H-U, Morón Merchante I, Nalamachu S, O'Brien J, Perrot S, Raffa RB

Journal of Pain Research 2012, 5:327-346

Published Date: 29 August 2012